The only reports available to date on the effects of MSCs in hemarthrosis conditions indicated that MSCs genetically engineered to overexpress factor VIII ameliorated HA after intra-articular injection in FVIII-deficient mice.11 This improvement was related to the production of coagulation factor VIII in a cell-based and gene-based therapy strategy. The gene discussed is F8; the disease is hemarthrosis.